API
< Back to all clusters
[BUSINESS] · India · 5 sources

started · updated

NPPA revises prices for 543 brands of anti-cancer drugs in India

The National Pharmaceutical Pricing Authority (NPPA) has announced revised maximum retail prices for 543 brands of anti-cancer drugs in India. The new pricing structure, which includes a 30 percent cap on trade margins for 137 identified non-scheduled anti-cancer medicines, is scheduled to take effect on November 9, 2026.

Significant price reductions have been reported for several treatments. For example, Dasatib 100 mg (30 tablets) will drop from 10,116 rupees to 1,380.32 rupees, and Bevacizumab 400 mg injection (16 ml vial) will decrease from 65,205.09 rupees to 8,956.75 rupees. Other notable reductions include Anarzole 1 mg tablets, which will fall from 695.76 rupees to 73 rupees, and Azacytidine injection, dropping from 6,337 rupees to 1,495.04 rupees.

While some individual drugs have seen price cuts exceeding 50 percent, reports indicate the overall reduction across all listed medicines is approximately 14 percent. The price revisions were prepared based on information provided by drug companies through late October 2026. The measure aims to reduce financial toxicity for patients, though experts note that true affordability must also address diagnostic, surgery, and travel costs.

Entities

Abbott Healthcare · Hetero Healthcare · India · Khandelwal Laboratories · National Pharmaceutical Pricing Authority · Samarth Life Sciences

Claims

What the coverage asserts, and how many sources carry each claim.